You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Claims for Patent: 10,265,311

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,265,311

Title:	Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
Abstract:	Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.
Inventor(s):	Eric Elenko, Andrew C. Miller, Philip E. Murray, III
Assignee:	Puretech Health LLC , Puretech Management Inc
Application Number:	US15/378,796
Patent Claims:	1. A method of treating a central nervous system disorder in a patient in need thereof, the method comprising orally administering between 75 mg and 300 mg xanomeline and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period, the central nervous system disorder being selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline. 2. The method of claim 1, wherein the central nervous system disorder is schizophrenia. 3. The method of claim 1, wherein the central nervous system disorder is Alzheimer's disease. 4. The method of claim 1, wherein the central nervous system disorder is Huntington's disease. 5. The method of claim 1, wherein the central nervous system disorder is Parkinson's disease. 6. The method of claim 1, wherein the central nervous system disorder is Lewy Body dementia. 7. The method of claim 1, wherein 225 mg of xanomeline and between 20 mg and 60 mg of trospium chloride are administered to the patient during the 24-hour period. 8. The method of claim 1, wherein the xanomeline and the trospium chloride are in the same dosage vehicle. 9. The method of claim 1, wherein the xanomeline and the trospium chloride are in different dosage vehicles. 10. The method of claim 1, wherein xanomeline is administered to the patient three times during the 24-hour period. 11. The method of claim 1, wherein trospium chloride is administered to the patient two times during the 24-hour period. 12. The method of claim 1, wherein between 20 mg and 60 mg of trospium chloride is administered to the patient during the 24-hour period. 13. The method of claim 1, wherein between 60 and 200 mg trospium chloride is administered to the patient during the 24-hour period. 14. The method of claim 1, wherein between 75 mg and 225 mg xanomeline and between 20 mg and 60 mg trospium chloride are administered to the patient during the 24-hour period. 15. The method of claim 1, wherein 300 mg xanomeline and between 60 mg and 200 mg trospium chloride are administered to the patient during a 24-hour period.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.